Search

A venture capital firm based in Boston is currently investing from its third fund of $220 million closed in 2015. The firm typically is the lead and first institutional investor in early-stage companies in the enterprise information technology (IT) space, including healthcare IT. The firm’s equity investment size ranges from $2-5 million. The firm is most active on the US East Coast and would consider opportunities from across the US. The firm plans to make 5-7 new investments in the following year

Within healthcare IT, the firm is seeking systems, technologies, and services that support clinical delivery to improve outcomes and efficiency of clinical care. The firm is not interested in consumer-facing products, genomic analytics, or life sciences software. The firm is looking for innovations that have demonstrated product-market fit in the form of recurring monthly revenue of $30K or more. Pre-revenue companies may be considered if there is a strong fit with its investment thesis. When it comes to healthcare IT investments, the firm often syndicates with strategic co-investors who understand the risks in the healthcare system, such as healthcare providers and payers.

The firm is looking for competent and experienced management teams with sector expertise. The firm brings in real world experience, industry knowledge and networks, and company-building skills to its portfolio companies. The firm takes a board seat post-investment.

Subscribe

Featured Posts

An interview with Zishan Haroon, Chairman and General Partner, Julz Co – By Claire Jeong, Research Analyst, LSN Earlier this week, I had the pleasure of speaking with Dr. Zishan “Z” Haroon, Chairman and General Partner of Julz Co. Z has been a tremendous supporter of the Redefining Early Stage Investments (RESI) Conference Series and a […]

By Gregory Mannix, Vice President International Business Development, LSN Life Science Nation’s Redefining Early Stage Investments (RESI) Conference series is a great opportunity to network and make connections with key players that can help move your company to the next phase. The RESI conference series, because of its unique focus and format, is by far […]

An interview with Life Science Nation’s CEO Dennis Ford regarding the up and coming Redefining Early Stage Investments conference series – By Ying Tam, Managing Director, Health Ventures, MaRS With the Redefining Early Stage Investments Conference headed back to MaRS on April 10th, Next Phase would like to revisit this interview between Dennis Ford (CEO, […]

A newly formed Delaware family office investment vehicle representing East Coast-based family interests is looking to invest in ground-breaking life science and medical device technologies. While the firm is very flexible in terms of investment size, they are generally looking to invest a minimum of $0.5 million per round. The firm is open to Investing […]

A venture capital firm partnered with the Chinese Government was founded in 2016, and focuses on cross-border investments. When investing, the firm doesn’t only provide financial capital, they also provide their global consulting services focused specifically on helping companies work across borders and in China. With the Chinese Government partnership, the firm seeks to bring […]